These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11567737)

  • 1. Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV.
    Altes HK; Price DA; Jansen VA
    Vaccine; 2001 Oct; 20(1-2):3-6. PubMed ID: 11567737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination.
    Altes HK; Wodarz D; Jansen VA
    J Theor Biol; 2002 Feb; 214(4):633-46. PubMed ID: 11851372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo.
    Seaman MS; Peyerl FW; Jackson SS; Lifton MA; Gorgone DA; Schmitz JE; Letvin NL
    J Virol; 2004 Jan; 78(1):206-15. PubMed ID: 14671102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
    Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Berzofsky JA
    J Immunol; 2007 Jun; 178(11):7211-21. PubMed ID: 17513770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
    Wodarz D; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.
    Seaman MS; Santra S; Newberg MH; Philippon V; Manson K; Xu L; Gelman RS; Panicali D; Mascola JR; Nabel GJ; Letvin NL
    J Virol; 2005 Apr; 79(8):4580-8. PubMed ID: 15795244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.
    Santra S; Barouch DH; Kuroda MJ; Schmitz JE; Krivulka GR; Beaudry K; Lord CI; Lifton MA; Wyatt LS; Moss B; Hirsch VM; Letvin NL
    J Virol; 2002 Jun; 76(12):6376-81. PubMed ID: 12021371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
    Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
    J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
    Gorse GJ; Patel GB; Belshe RB;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
    Tobery TW; Siliciano RF
    J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular HIV-1 immune responses in natural infection and after genetic immunization.
    Calarota SA; Wahren B
    Scand J Infect Dis; 2001; 33(2):83-96. PubMed ID: 11233857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.
    Barouch DH; Craiu A; Santra S; Egan MA; Schmitz JE; Kuroda MJ; Fu TM; Nam JH; Wyatt LS; Lifton MA; Krivulka GR; Nickerson CE; Lord CI; Moss B; Lewis MG; Hirsch VM; Shiver JW; Letvin NL
    J Virol; 2001 Mar; 75(5):2462-7. PubMed ID: 11160750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.